New Alzheimer’s drug rejected for widespread NHS use

The National Institute for Health and Care Excellence (NICE) has ruled that a new pioneering drug Donanemab, that can treat Alzheimer’s, does not "currently demonstrate value for the NHS". It’s the second time a new treatment has been rejected by the health spending watchdog in the past few months. Read more: https://news.sky.com/story/pioneering-alzheimers-drug-rejected-for-widespread-use-in-nhs-in-england-13239378 #alzheimer #nhs #skynews SUBSCRIBE to our YouTube channel for more videos: http://www.youtube.com/skynews Follow us on Twitter: https://twitter.com/skynews Like us on Facebook: https://www.facebook.com/skynews Follow us on Instagram: https://www.instagram.com/skynews Follow us on TikTok: https://www.tiktok.com/@skynews For more content go to http://news.sky.com and download our apps: Apple https://itunes.apple.com/gb/app/sky-news/id316391924?mt=8 Android https://play.google.com/store/apps/details?id=com.bskyb.skynews.android&hl=en_GB Sky News Daily podcast is available for free here: https://podfollow.com/skynewsdaily/ For analysis of world events, tap here for The World With Richard Engel and Yalda Hakim: https://podfollow.com/the-world-with-richard-and-yalda Sky News videos are now available in Spanish here/Los video de Sky News están disponibles en español aquí: https://www.youtube.com/channel/UCzG5BnqHO8oNlrPDW9CYJog To enquire about licensing Sky News content, you can find more information here: https://news.sky.com/info/library-sales